Janakiraman Subramanian, MD
In recent years, several advances have been made in the lung cancer space, particularly in squamous non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), said Janakiraman Subramanian, MD, and groundbreaking data from 2 key pivotal trials—KEYNOTE-407 and IMpower133—have resulted in practice-changing outcomes for these patients.
on Advanced Non–Small Cell Lung Cancer, Subramanian, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discussed ongoing advances and remaining challenges in the field of lung cancer.
OncLive: Could you discuss recent trials that have led to major advances in lung cancer treatment?
: The KEYNOTE-407 study was [conducted] primarily [in patients with] squamous cell lung cancer and looked at giving chemotherapy plus pembrolizumab, which is a PD-1 inhibitor. Patients were randomized to receive carboplatin plus paclitaxel plus pembrolizumab versus carboplatin/paclitaxel alone. They also got placebo on that arm. They were looking at the co-primary endpoints with PFS and OS and patients were randomized to either arm, irrespective of their PD-L1 status.
... to read the full story